• Store
  • COVID-19 Info
  • APHON Swag

Evidence Based Practice Clinical Guideline Review

Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update

Author(s): Priya Patel, Paula D. Robinson, Jennifer Thackray, Jacqueline Flank, Mark T. Holdsworth, Paul Gibson, Andrea Orsey, Carol Portwine, Jason Freedman, Jennifer R.Madden, Robert Phillips, Lillian Sung, L. Lee Dupuis

Date of publication: 2017| Date of Review: March 31, 2019

Method of Review: A subcommittee of the Evidence Based Practice and Research Committee of the Association of Pediatric Hematology/Oncology Nurses conducted a group review of the clinical recommendations using the AGREE II criteria1. The committee had an overall assessment of approval for endorsement.

Review Summary: This is an update of the 2013 clinical practice guideline which provides clinicians with recommendations on medications to treat acute chemotherapy-induced nausea and vomiting (CINV) in children. The update is focused on more recent pediatric dosing changes for aprepitant and palonosetron, and is provided pending a full guideline update.

The systematic review was very well done, and the recommendations are quite clear.  A multi-disciplinary team was involved in the entire process. The update is important because there are now more agents available for use, and better control of nausea and vomiting is possible.  Issues regarding children < 6 months of age are addressed. Nurses caring for pediatric oncology patients will find the recommendations useful in their practice. 

Recommendation for use: Recommended for use in pediatric oncology.

Access Guideline Return to Evidence Based Practice

1AGREE Next Steps Consortium (2009). The AGREE II Instrument [Electronic version]. Retrieved May, 2018, from www.agreetrust.org